Wealth Enhancement Trust Services’s MoonLake Immunotherapeutics MLTX Stock Holding History
Bought
Maintained
Sold
Other funds holding MLTX
Wealth Enhancement Trust Services's MLTX Position: Q3 2026 in Review
Wealth Enhancement Trust Services sold out of MoonLake Immunotherapeutics (MLTX) in Q3 2026, closing a stake of 49 shares — an estimated $954 sold.
Wealth Enhancement Trust Services first reported a position in MLTX in Q2 2026 and held it in 1 quarter. The position peaked at $954 in Q2 2026. 170 funds tracked by Wall St. Rank hold MLTX as of Q3 2026.
- Wealth Enhancement Trust Services reported no remaining MoonLake Immunotherapeutics position as of Q3 2026 after selling out during the quarter.
- Wealth Enhancement Trust Services sold 49 MoonLake Immunotherapeutics shares in Q3 2026, an estimated $954.
- Wealth Enhancement Trust Services first reported a position in MoonLake Immunotherapeutics in Q2 2026 and held it in 1 quarter.
- Wealth Enhancement Trust Services's MoonLake Immunotherapeutics position peaked at $954 in Q2 2026.
- 170 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q3 2026.
Based on Wealth Enhancement Trust Services's 13F filing for Q3 2026, filed 7 Oct 2026.